[{"data":1,"prerenderedAt":642},["ShallowReactive",2],{"content-site-settings":3,"site-map-\u002Fsite-map":45,"site-map-locations":406},{"id":4,"extension":5,"meta":6,"stem":43,"__hash__":44},"dataFiles\u002Fdata\u002Fsite.json","json",{"en":7},{"siteDetails":8,"cookieControl":12,"siteLogo":16,"mainNav":21,"preNav":32,"stickyNav":33,"footerContent":34},{"organisationName":9,"siteName":10,"siteUrl":11},"Scancell Ltd","The ModiFY Study","https:\u002F\u002Fmodi-1-study.digitrial.com\u002F",{"cookieModalTitle":13,"cookieModalText":14,"nonNecessaryCookiesUsed":15},"Cookies used on this site","This website only uses non-necessary cookies to remember where you are in the process and to learn about how people view the information. We do NOT use cookies that directly identify anyone. For the best experience please click Accept all below.",true,{"url":17,"alt":18,"width":19,"height":20},"modify-logo@2x.png","Home",156.44,80,[22,25,29],{"title":23,"url":24},"Taking part","\u002Ftaking-part",{"title":26,"url":27,"target":28,"external":28},"About the study","\u002Fabout\u002F",false,{"title":30,"url":31,"target":28,"external":28},"Contact","\u002Fcontact\u002F",[],[],{"footerLogo":35,"footerCol1":39,"footerCol2":40,"footerCol3":41,"additionalInfo":42},{"url":36,"alt":37,"width":38,"height":38},"modify-logo-alt@2x.png","Scancell study logo",null,"Email: [modifyenquiries@scancell.co.uk](mailto:modifyenquiries@scancell.co.uk)\n\nTel: +44 (0)1865 582690","Scancell Ltd,\\\nBellhouse Building,\\\nSanders Road,\\\nOxford Science Park,\\\nOxford,\\\nOX4 4GD","[Privacy policy](\u002Fprivacy)\n[Cookie policy](\u002Fcookies)\n[Accessibility statement](\u002Faccessibility)\n[Site map](\u002Fsite-map)","This is a digitrial site made by morph.co.uk.","data\u002Fsite","wJ7sB88ZpZ4Gz5LpO4H3iQkv7sKS81LNYZ210IMhAb0",[46,173,194,231,255,338,358],{"id":47,"title":26,"body":38,"description":38,"extension":5,"meta":48,"navigation":15,"path":169,"seo":170,"stem":171,"__hash__":172},"contentPages\u002Fpages\u002Fabout.en.json",{"pageTitle":26,"pageMetadata":49,"page_content":50},{"htmlTitle":26,"htmlDesc":26},[51,61,93,101,143],{"type":52,"title":53,"text":54,"image":55,"sectionSettings":60},"page_header","# About the study","A Phase 1\u002F2, Multicentre, Open-Label Study of Modi-1 in patients with head and neck cancer, renal cancer, and triple negative breast cancer",{"url":56,"alt":57,"width":58,"height":59},"modify-header-image-13@2x.png","",1100,720,{"sectionLabel":26},{"type":62,"settings":63,"text":66,"image":67,"iconList":71,"sectionSettings":89},"text_and_image",{"imgWidth":64,"imgPosition":65},"half-width","bottom","The study proposes a trial of a new vaccine, Modi-1, that consists of a combination of specific peptides. The Modi-1 peptides are combined with an adjuvant, which is designed to increase the activity of the vaccine.",{"width":68,"height":69,"url":70},460,300,"modify-content-image-9.png",[72,77,81,85],{"icon":73,"content":76},{"iconSize":74,"iconName":75},"lg","content-stethoscope","The aim of this study is to investigate the safety and effectiveness of the Modi-1 vaccine(s) in participants with head and neck cancer, renal cancer, and triple negative breast cancer.",{"icon":78,"content":80},{"iconSize":74,"iconName":79},"content-vial","In this trial, Modi-1 will be administered, either on its own (monotherapy) or in combination with a Checkpoint Inhibitor (which is given as standard of care).",{"icon":82,"content":84},{"iconSize":74,"iconName":83},"content-head","In addition, a randomized cohort is included in this study. This cohort is available to patients with head and neck cancer who are scheduled to have their tumour removed, intending to cure their cancer. In this cohort the local impact of Modi-1 (with or without pembrolizumab) will be assessed by looking at the removed tumour.",{"icon":86,"content":88},{"iconSize":74,"iconName":87},"content-syringe","Modi-1 will be administered intradermally (just under the top layer of skin). The MicronJet600™ micro-needle device will be used to administer the vaccine and contains three very small needles.",{"textAlign":90,"sectionLabel":91,"theme":92},"left","More information","mid",{"type":94,"text":95,"componentName":96,"componentOptions":97,"sectionSettings":99},"text_and_component","## Locations","StudyLocationsMap",{"mapTitle":98},"UK",{"sectionLabel":100},"Study locations map",{"type":102,"settings":103,"text":107,"cards":108,"sectionSettings":141},"text_and_cards",{"headerLevel":104,"headerFontSize":104,"maxCardsPerRow":104,"wholeClickable":28,"cardTheme":105,"alignCards":106,"alignCardContent":106},"3","primary","center","## Information about the ModiFY Study",[109,116,121,126,131,136],{"type":110,"icon":111,"title":114,"summary":115},"card_icon_text",{"iconName":112,"iconSize":113},"content-chart-1","xl","Sample size","**How many patients will be included?**\n\nUp to 138 patients",{"type":110,"icon":117,"title":119,"summary":120},{"iconName":118,"iconSize":113},"content-cross","Investigational Product","**What drug are we testing?**\n\nModi-1 vaccine",{"type":110,"icon":122,"title":124,"summary":125},{"iconName":123,"iconSize":113},"content-seedling","Study Sponsor","**Scancell Ltd**\n\nScancell is focused on developing novel immunotherapies for the treatment of cancer and infectious disease",{"type":110,"icon":127,"title":129,"summary":130},{"iconName":128,"iconSize":113},"content-edit","Study Design","A Phase 1\u002F2 study to assess the **safety**, **tolerability** (if there are any side effects, are they bearable?), **immunological activity** (does it trigger the bodies immune systems defences?) and **preliminary efficacy** (how well does it work?) of the Modi-1 vaccine in patients with head and neck cancer, renal cancer, and triple negative breast cancer",{"type":110,"icon":132,"title":134,"summary":135},{"iconName":133,"iconSize":113},"content-pie-chart","Primary outcomes","**What is the study Measuring?**\n\n* Does Modi-1 trigger an immune response?\n* Safety of Modi-1: The number of Modi-1 related side effects",{"type":110,"icon":137,"title":139,"summary":140},{"iconName":138,"iconSize":113},"content-person","Study Population","**What types of cancer is this study targeting?**\n\n 1. Head and Neck Cancer\n2. Renal Cancer\n3. Triple Negative Breast Cancer",{"sectionLabel":142,"textAlign":106},"Information about the Study",{"type":102,"settings":144,"text":147,"cards":148,"sectionSettings":167},{"headerLevel":104,"headerFontSize":104,"maxCardsPerRow":145,"wholeClickable":28,"cardTheme":146,"numberedCards":28,"alignCards":90,"alignCardContent":90},"4","secondary","## Study Team",[149,156,160,164],{"type":150,"image":151,"title":154,"summary":155},"card_image_text",{"url":57,"width":152,"height":153},900,576,"Christian Ottensmeier","**Chief Investigator**\n\nChristian is a medical oncologist with a sub-specialty in thoracic malignancies, skin cancer, and immunotherapy.",{"type":150,"image":157,"title":158,"summary":159},{"url":57,"width":152,"height":153},"Fayaz Master","**Head of Clinical Operations at Scancell**\n\nFayaz has over 20 years of clinical operations experience in early and late-stage global oncology clinical development.",{"type":150,"image":161,"title":162,"summary":163},{"url":57,"width":152,"height":153},"Robert Miller","**Medical Director at Scancell**\n\nRobert has over 32 years of experience in drug development. He is a Fellow of the Royal College of Surgeons and Fellow of the Faculty of Pharmaceutical Medicine and Royal Society of Medicine.",{"type":150,"title":165,"summary":166},"Joe Thornton","**Clinical Project Manager**\n\nJoe has over 6 years of clinical operations experience in early and late-stage global oncology clinical development.",{"sectionLabel":168},"Study Team","\u002Fpages\u002Fabout.en",{"title":26},"pages\u002Fabout.en","GImtHFRfKAB9TVyv4-RC0_7x3UdWcQZF8RVA48hNkp8",{"id":174,"title":175,"body":38,"description":38,"extension":5,"meta":176,"navigation":15,"path":190,"seo":191,"stem":192,"__hash__":193},"contentPages\u002Fpages\u002Faccessibility.en.json","Accessibility statement",{"pageTitle":175,"pageMetadata":177,"page_content":178},{"htmlTitle":175,"htmlDesc":175},[179,185],{"type":52,"title":180,"image":181,"sectionSettings":184},"# Accessibility statement",{"url":182,"alt":183,"width":68,"height":69},"modify-content-image-15.png","Family looking at device",{"sectionLabel":175},{"type":186,"text":187,"sectionSettings":188},"text","This study is committed to ensuring digital accessibility for people with disabilities. We are continually improving the user experience for everyone, and applying the relevant accessibility standards.\n\n## Conformance status\n\nThe \u003Ca href=\"https:\u002F\u002Fwww.w3.org\u002FWAI\u002Fstandards-guidelines\u002Fwcag\u002F\" target=\"_blank\">Web Content Accessibility Guidelines (WCAG)\u003C\u002Fa> define requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA. \n\n**This site is conformant with WCAG 2.2 level AA** and **partially conformant with WCAG 2.2 level AAA**. Partially conformant means that some parts of the content do not fully conform to the AAA accessibility standard.\n\n### Specific exceptions to WCAG 2.2 level AA compliance\n\n* Third party frameworks used to build this app - e.g. \u003Ca href=\"https:\u002F\u002Fnuxtjs.org\u002F\" target=\"_blank\">Nuxt\u003C\u002Fa> - may contain some minor accessibility issues which are not editable by Morph. This includes, for instance, CSS loading animations the duration of which has been to set to longer than 5 seconds. We have attempted to ensure that these exceptions do not impact negatively on user experience.\n\n## Accessibility Features\n\n- All page content can be navigated using keyboard only\n- Skip to main content link available on all pages\n- ARIA labels and landmarks for screen reader users\n- Semantic HTML structure throughout\n- Sufficient color contrast ratios (minimum 4.5:1 for normal text)\n- Respects user preferences for reduced motion\n- Form labels and error messages clearly associated with inputs\n- Video content includes transcripts\n- Focus indicators are visible on all interactive elements\n\n## Design Decisions\n\n**Focus Indicators:** We rely on browser default focus indicators rather than custom styling. This approach ensures focus is always visible on all interactive elements and allows user-applied customisation through system-wide assistive technology to work as expected without interference.\n\n**Keyboard Navigation:** When using in-page content links with the keyboard, focus is applied to the target content for screen readers and keyboard users. The page does not auto-scroll to prevent disorientation, allowing users to control their scrolling experience.\n\n## Technical Specifications\n\nThis website's accessibility relies on the following technologies:\n\n- HTML5\n- CSS3\n- JavaScript\n- ARIA (Accessible Rich Internet Applications)\n\nThe website is designed to be compatible with assistive technologies including screen readers.\n\n## Testing\n\nThis website has been tested for accessibility using:\n\n- Keyboard-only navigation\n- Multiple screen readers (NVDA, VoiceOver)\n- Automated testing tools\n- Manual testing against WCAG 2.2 Level AA and AAA criteria\n\nWe have made every effort to ensure that all content is accessible, although we are aware of minor inconsistencies in how some screen readers handle complex features such as video transcripts.\n\nWhen navigating inside a page using the keyboard, the page content links do not scroll to the target content. However, focus is applied to the target content so screen readers will be directed to the appropriate content.\n\n## Limitations (Level AAA Only)\n\n**Focus Appearance (WCAG 2.4.13 - Level AAA):** While all focus indicators are visible (meeting Level AA requirements), browser default focus indicators may not consistently meet the enhanced AAA requirements for focus appearance (minimum 2px thickness and 3:1 contrast ratio) across all browsers and contexts.\n\n**Target Size (WCAG 2.5.5 - Level AAA):** Some interactive elements such as checkboxes, do not meet the enhanced AAA requirement of 44px × 44px minimum target size. All interactive elements meet the Level AA requirements for basic usability and are appropriately spaced to minimize accidental activation.\n\n## Feedback\n\nWe welcome your feedback on the accessibility of this website. If you experience any difficulty accessing content or have suggestions for improvement, please contact us at admin@morph.co.uk.\n\n## Assessment Information\n\n- **Evaluation method:** Self-assessment\n- **Statement last reviewed:** February 2026\n- **WCAG version:** 2.2\n- **Conformance level:** Level AA (conformant), Level AAA (partially conformant)",{"sectionLabel":189},"Conformance status","\u002Fpages\u002Faccessibility.en",{"title":175},"pages\u002Faccessibility.en","2GtNLO_UEddvE9YVl12dNFQMebjzq490K_yX1bMyttU",{"id":195,"title":30,"body":38,"description":38,"extension":5,"meta":196,"navigation":15,"path":227,"seo":228,"stem":229,"__hash__":230},"contentPages\u002Fpages\u002Fcontact.en.json",{"pageTitle":30,"pageMetadata":197,"page_content":198},{"htmlTitle":30,"htmlDesc":30},[199,206],{"type":52,"title":200,"text":201,"image":202,"sectionSettings":204},"# Contact Us","If, at any time, you would like further information about this study you may email us, call or write to us.",{"url":203,"width":58,"height":59},"modify-header-image-2@2x.png",{"textAlign":90,"sectionLabel":205},"Contact Us",{"type":102,"settings":207,"cards":209,"text":57,"sectionSettings":225},{"headerLevel":208,"headerFontSize":145,"maxCardsPerRow":104,"wholeClickable":28,"cardTheme":105,"alignCards":106,"alignCardContent":106},"2",[210,215,220],{"type":110,"title":211,"summary":212,"icon":213},"Email:","modifyenquiries@scancell.co.uk",{"iconName":214,"iconSize":113},"content-mail",{"type":110,"title":216,"summary":217,"icon":218},"Call us","+44 (0)1865 582690",{"iconName":219,"iconSize":113},"content-mobile",{"type":110,"icon":221,"summary":223,"title":224},{"iconSize":113,"iconName":222},"content-speech-bubble","Attention of: ModiFY Enquiries\n\n\r\nScancell Ltd,\r\nBellhouse Building,\r\nSanders Road,\r\nOxford Science Park,\r\nOxford,\r\nOX4 4GD","Write to Us",{"textAlign":90,"sectionLabel":226},"Contact cards","\u002Fpages\u002Fcontact.en",{"title":30},"pages\u002Fcontact.en","QdVAwYuYJgaN8_SgnZjsrQVzy7shvdKoHHauef_5neQ",{"id":232,"title":233,"body":38,"description":38,"extension":5,"meta":234,"navigation":15,"path":251,"seo":252,"stem":253,"__hash__":254},"contentPages\u002Fpages\u002Fcookies.en.json","Cookie Policy",{"pageTitle":233,"pageMetadata":235,"page_content":236},{"htmlTitle":233,"htmlDesc":233},[237,242,246],{"type":52,"title":238,"image":239,"sectionSettings":241},"# Cookie Policy",{"url":240,"alt":57,"width":58,"height":59},"modify-header-image-12@2x.png",{"sectionLabel":233},{"type":186,"text":243,"sectionSettings":244},"## Website Cookies\n\nOur website uses necessary and non-necessary cookies. The necessary cookies are required for the website to function the right way, and they do not collect any of your personally identifiable data.\n\nThe non-necessary cookies used on our websites are used for understanding how the website is used so that we can provide you with a better user experience and help speed up your future interactions with our website.\n\n### Types of cookies we use\n\n**Necessary**: Some cookies are essential for you to be able to experience the full functionality of our site. They allow us to keep track of your progress through the site as well as enabling access to core functionality such as video playback. They do not collect or store any personal information.\n\n**Non-necessary**: These cookies store information like the number of visitors to the website, the number of unique visitors, which pages of the website have been visited, the source of the visit etc. These data help us understand and analyse how well the website performs and where it needs improvement.\n\n### Specific cookies we use\n\n#### Vimeo:\n\nPages that embed a Vimeo video load the Vimeo player when the page opens, so the cookies below may be set as soon as you open such a page — you do not have to press play. Pages with no video do not set them. These cookies do not track individuals. If you accept cookies, then choose to opt out later these cookies will not be deleted, but will stop tracking data after you have opted out.\n\n##### Cookie name: Player\n\n**Purpose**: Stores preferences for vimeo player controls (i.e. volume, stream quality, captions).\n\n**Necessary**: no\n\n**Expires in**: 1 year\n\n##### Cookie name: Vuid\n\n**Purpose**: Vimeo-generated ID used for generating analytics information for the video owner.\n\n**Necessary**: no\n\n**Expires in**: 2 years\n\n##### Cookie name: __cf_bm\u002F player_clearance\n\n**Purpose**: Cookies set by Vimeo's own Cloudflare protection to tell real visitors from bots.\n\n**Necessary**: yes\n\n**Expires in**: 30 minutes\u002F 7 days\n\n#### Our hosting provider (Cloudflare):\n\nThis website is served through Cloudflare, which sets the cookies below on our own domain to protect the site. They are set on **every** page, whether or not it contains a video, and are required for the site to be served securely.\n\n##### Cookie name: cf_clearance\n\n**Purpose**: Records that your browser passed Cloudflare's bot\u002Fsecurity check, so you are not re-challenged on every page.\n\n**Necessary**: yes\n\n**Expires in**: up to 1 year\n\n##### Cookie name: _cfuvid\n\n**Purpose**: Cloudflare cookie used to enforce rate limiting rules.\n\n**Necessary**: yes\n\n**Expires in**: current session only\n\n#### Cookie Name: _ga, _ga*\n\n**Purpose**: Used by Google Analytics to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. Stores information anonymously and assigns a randomly generated number to identify unique visitors.\n\n**Necessary**: no\n\n**Expires in**:  2 years\n\n## LocalStorage data\n\nWe also store data in your browser to keep track of your cookie preferences. This is stored in [LocalStorage](https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FWeb_storage). This data is anonymous, persistent and necessary for the functioning of the site.\n\n### LocalStorage Key: GDPR:accepted\n\n**Purpose**: This localStorage property records whether you have accepted non-necessary cookies from this website. It is set only once you make a choice.\n\n**Necessary**: yes\n\n**Expires in**: permanent\n\n### Vimeo Local Storage\n\nVimeo uses browser local storage to remember video player preferences (such as volume and playback settings). These storage items are functional, are not used for advertising and store no identifiable information.\n\nExample keys may include\n\n* LOCAL_STORAGE_ID_VIMEO_PLAYER\n* sync_active\n\n**Necessary**: yes\n\n**Expires in**: variable\n\n## How can I control my cookie preferences?\n\nYou can edit your cookie preferences by clicking the link 'View and edit cookie settings' in the section 'What is my current cookie consent status?' below.\n\nIf you decide to 'Opt out' of non-necessary cookies, they may remain in your browser but will no longer be used to send data about your visit to the third party analytics service.\n\nIn addition to this, different browsers provide different methods to block and delete cookies used by websites. You can change the settings of your browser to block\u002Fdelete the cookies. To find out more out more on how to manage and delete cookies, visit [wikipedia.org](https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FHTTP_cookie), [www.allaboutcookies.org.](http:\u002F\u002Fwww.allaboutcookies.org\u002F)\n\n## Contact Us\n\nIf you have any questions about the content of this page or problems with the website, please contact us at: admin@morph.co.uk",{"sectionLabel":245},"Website Cookies",{"type":94,"text":247,"componentName":248,"sectionSettings":249},"## What is my current cookie consent status?","CookiesOptInOut",{"sectionLabel":250},"View and Edit Cookie Settings","\u002Fpages\u002Fcookies.en",{"title":233},"pages\u002Fcookies.en","rjibDM8AE-TkXIQZ6ogGq2BncOHNupB2-NDIkigChS4",{"id":256,"title":257,"body":38,"description":38,"extension":5,"meta":258,"navigation":15,"path":334,"seo":335,"stem":336,"__hash__":337},"contentPages\u002Fpages\u002Findex.en.json","Home page",{"pageTitle":10,"pageMetadata":259,"page_content":260},{"htmlTitle":10,"htmlDesc":10},[261,270,278,287,295,304],{"type":52,"title":262,"text":263,"image":264,"settings":266,"sectionSettings":267},"# The ModiFY Study","The ModiFY Study is a first-in-human clinical trial in patients with head and neck cancer, renal cancer, and triple negative breast cancer",{"url":265,"alt":57,"width":58,"height":59},"modify-header-image-3@2x.png",{"imgWidth":64},{"sectionLabel":268,"customClass":269,"theme":105},"The DRIFT Study","page_header_bg_2",{"type":271,"text":272,"video":273,"sectionSettings":277},"text_and_video","## The ModiFY study: Overview\n\nThe ModiFY clinical trial, is being conducted in hospitals across the UK, so that researchers can assess whether the Modi-1 vaccine when given to patients with specific cancer types:\n\n1. Is safe at different doses\n2. Can trigger the immune system to fight cancer \n3. Is effective at shrinking tumours \n\nThe clinical trial is recruiting patients with the following advanced cancer types:\n\n1. (HPV negative) Head and Neck Cancer\n2. Renal Cell Cancer \n3. Triple Negative Breast Cancer \n\nThe study is also recruiting patients with Head and Neck Cancer that are planning to undergo surgery. \n\nThe short video below provides more information about the study.",{"vimeoId":274,"videoTitle":275,"videoTranscript":276,"offlineVideo":57},"808361835\u002F68520f5b89","ModiFY Participant Information Animation","The ModiFY Study...is recruiting patients with triple negative breast, head and neck, ovarian or kidney cancers.\n\nThe study will investigate a new immunotherapy, called Modi-1, to see if it can be used safely in these advanced cancers.\n\nModi-1 is a vaccine that contains three peptides. Peptides are small parts of a protein designed to help your immune system fight cancer.\n\nThis is an experimental treatment that may help treat your cancer by triggering an immune response so that your immune system can shrink your tumour.\n\nAs with all drugs there are potential side effects, so your study doctor will monitor you closely throughout the study.\n\nThe ModiFY Study is recruiting approximately 138 patients in up to 20 cancer centres across the UK.\n\nPatients with your type of cancer are invited to participate…if your doctor believes you are eligible for this type of immunotherapy.\n\nIf you are currently receiving a course of checkpoint inhibitors these will continue as planned.\n\nYour doctor will provide you with more information about the study…and if you decide to take part will ask you to sign a consent form.\n\nTaking part in the study is voluntary. You are free to withdraw at any time without giving a reason\n\nIf you do withdraw, or don’t want to take part, you are still offered the same standard of care for your cancer.\n\nAll patients enrolled in the study complete a number of screening examinations for up to 28 days before the treatment.\n\nThis involves visiting the clinic so we can collect information, carry out tests and in some cases take samples.\n\nMost participants will receive Modi-1 5 times within the first 6 months…then once every 3 months for approximately…2 years, or until your doctor decides the treatment is complete. Whichever comes first.\n\nFollow up visits are scheduled at regular intervals…to collect information, take blood tests and carry out scans to monitor your cancer.\n\nAll medical information and any samples collected will be stored or disposed of, legally and securely.\n\nBy taking part in this study you are helping doctors learn more about how to treat cancer.\n\nFor more information... Send us an email or contact your nearest participating hospital.\n\nDetails can be found on our website.",{"sectionLabel":275},{"type":62,"settings":279,"title":281,"text":282,"image":283,"sectionSettings":285},{"imgWidth":64,"imgPosition":280},"top","## Objectives","Researchers across the UK aim to address the following questions in the ModiFY clinical trial:\n\n* Is Modi-1 vaccination safe at different doses?\n* Are any side effects related to Modi-1 tolerable?\n* How strongly does Modi-1 trigger the immune system to fight cancer?\n* How effective is Modi-1 in shrinking tumours?\n\nPatients will be treated with Modi-1 vaccine on its own (monotherapy), and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab (where these are standard of care).",{"url":284,"alt":57,"width":68,"height":69},"modify-content-image-5.png",{"sectionLabel":286},"Background",{"type":271,"text":288,"video":289,"sectionSettings":293},"## How does the Modi-1 vaccine work?\n\nThis short video explains how the Modi-1 vaccine works.",{"vimeoId":290,"videoTitle":291,"videoTranscript":292},"808371130\u002Fbc2de8ee0c","Modi-1: How does the Modi-1 vaccine work?","Modi-1 is a vaccine that may help treat your cancer by boosting your immune system to shrink your tumour.\n\nModi-1 contains three peptides, these peptides are also known as antigens. An antigen can be any substance that triggers an immune response in your body.\n\nThe Modi-1 antigens are small parts of a protein designed to help your immune system fight cancer.\n\nOne important group of cells in the immune system are the antigen presenting cells or APCs.\n\nWhen we inject you with Modi-1, the three antigens are taken up by APCs in your blood. The APCs display the three Modi-1 antigens on its cell surface.\n\nAnother important group of cells in the immune system are the T cells. T cells are white blood cells, otherwise also known as lymphocytes.\n\nWhen a T cell sees an APC with the Modi-1 antigens on its surface, it recognises it. This signal causes the T cell to become ‘activated’.\n\nCancer cells can also have the antigens on their surface that look like the three Modi-1 antigens.\n\nWhen activated T cells see these cancer cells, they can then attack and destroy them.",{"textAlign":90,"sectionLabel":294},"Modi-1: Mechanism of action",{"type":62,"settings":296,"text":297,"title":298,"image":299,"sectionSettings":302},{"imgWidth":64,"imgPosition":65},"Oncologists across the UK are recruiting patients to this clinical trial with Head and Neck Cancer, Renal Cell Cancer and Triple Negative Breast Cancer. If you are not currently receiving treatment or are starting treatment with a checkpoint inhibitor, for any one of these cancer types and are interested to learn more about the ModiFY study please inform your cancer doctor and\u002For the research team at the e-mail address: modifyenquiries@scancell.co.uk.","## Status",{"url":182,"width":300,"height":301},920,600,{"textAlign":90,"sectionLabel":303},"Status",{"type":102,"settings":305,"cards":306,"sectionSettings":332},{"headerLevel":104,"headerFontSize":104,"maxCardsPerRow":104,"wholeClickable":15,"numberedCards":28,"alignCards":90,"alignCardContent":90},[307,315,324],{"type":150,"image":308,"title":310,"summary":311,"links":312},{"url":309,"width":152,"height":153},"modify-card-image-1@2x.png","Taking Part","Find out more about what will happen if you decide to take part",[313],{"title":314,"url":24,"external":28,"target":28},"Go to 'Taking Part'",{"type":150,"image":316,"title":318,"summary":319,"links":320},{"url":317,"width":152,"height":153},"modify-card-image-2@2x.png","About the Study","Learn more about the ModiFY Study",[321],{"title":322,"url":323},"Got to 'About the Study'","\u002Fabout",{"type":150,"image":325,"title":205,"summary":327,"links":328},{"url":326,"width":152,"height":153},"modify-card-image-3@2x.png","Do you have any questions or would like to speak to a member of the research team?",[329],{"title":330,"url":331},"Get in touch","\u002Fcontact",{"sectionLabel":333},"Benefits of screening for type 1 diabetes:","\u002Fpages\u002Findex.en",{"title":257},"pages\u002Findex.en","EGj6qP67RAyDN3sITYFEJ7CTqn8W_2Y-2Mi6Adg65r4",{"id":339,"title":340,"body":38,"description":38,"extension":5,"meta":341,"navigation":15,"path":354,"seo":355,"stem":356,"__hash__":357},"contentPages\u002Fpages\u002Fprivacy.en.json","Privacy policy",{"pageTitle":342,"pageMetadata":343,"page_content":344},"Privacy page",{"htmlTitle":340,"htmlDesc":340},[345,350],{"type":52,"title":346,"image":347,"sectionSettings":349},"# Privacy policy",{"url":348,"alt":57,"width":58,"height":59},"modify-header-image-6@2x.png",{"sectionLabel":340},{"type":186,"text":351,"sectionSettings":352},"This website has been designed and developed by Morph Media Limited specifically for this clinical trial. We understand that your privacy is important to you and that you care about how your personal data is used. We respect and value the privacy of all of our customers and suppliers’ data and will only collect and use personal data in ways that are described here, and in a way that is consistent with our obligations and your rights under the law.\n\n## 1. Information about us\n\nMorph Media Limited, a limited company (company number 13801210).\n\nMain trading address: 8 New Shambles, Kendal, LA9 4TS\n\nVAT Reg: 400 693 620\n\nData Protection Officer: Matthew Brook\n\nEmail address: info@morph.co.uk\n\nTelephone number: 01524 88 42 88\n\nPostal Address: 8 New Shambles, Kendal, LA9 4TS\n\n## 2. What does this policy cover?\n\nThis Privacy Policy relates specifically to this website only and explains how we use your personal data on the site: how it is collected, how it is held, and how it is processed. It also explains your rights under the law relating to your personal data.\n\n## 3. What is personal data?\n\nPersonal data is defined by the General Data Protection Regulation (EU Regulation 2016\u002F679) (the “GDPR”) as ‘any information relating to an identifiable person who can be directly or indirectly identified in particular by reference to an identifier’. Personal data is, in simpler terms, any information about you that enables you to be identified. Personal data covers obvious information such as your name and contact details, but it also covers less obvious information such as identification numbers, electronic location data, and other online identifiers. The personal data that we use is set out in Part 5, below.\n\n## 4. What are your rights?\n\nUnder the GDPR, you have the following rights, which we will always work to uphold:\n\n1. The right to be informed about our collection and use of your personal data. This Privacy Policy should tell you everything you need to know, but you can always contact us to find out more or to ask any questions using the details in Part 11.\n2. The right to access the personal data we hold about you. Part 10 will tell you how to do this.\n3. The right to have your personal data rectified if any of your personal data held by us is inaccurate or incomplete. Please contact us using the details in Part 11 to find out more.\n4. The right to be forgotten, i.e. the right to ask us to delete or otherwise dispose of any of your personal data that we have. Please contact us using the details in Part 11 to find out more.\n5. The right to restrict (i.e. prevent) the processing of your personal data.\n6. The right to object to us using your personal data for a particular purpose or purposes.\n7. The right to data portability. This means that, if you have provided personal data to us directly, we are using it with your consent or for the performance of a contract, and that data is processed using automated means, you can ask us for a copy of that personal data to re-use with another service or business in many cases.\n8. Rights relating to automated decision-making and profiling. We do not use your personal data in this way.\n\nFor more information about our use of your personal data or exercising your rights as outlined above, please contact us using the details provided in Part 11.\n\nFurther information about your rights can also be obtained from the Information Commissioner’s Office or your local Citizens Advice Bureau.\n\nIf you have any cause for complaint about our use of your personal data, you have the right to lodge a complaint with the Information Commissioner’s Office.\n\n## 5. What personal data do we collect when you visit this website?\n\nYou may visit the Site without telling us who you are or revealing any personally identifiable information about you. \n\nThe website is hosted by Cloudflare using their Workers service. Cloudflare maintains log data about events on its network. Some of this log data will include information about visitors to and\u002For authorized users of a customer’s domains, networks, websites, application programming interfaces (“APIs”), or applications. This metadata contains extremely limited personal data, most often in the form of IP addresses. Cloudflare process this type of information on behalf of its  customers in its main data centers in the U.S. and Europe for a limited period of time.\n\nFor full details of Cloudflare's approach to privacy and data protection is available using the following link, although please bear in mind that these are wide-ranging documents with many documents not directly relevant to the service we use: \u003Ca href=\"https:\u002F\u002Fwww.cloudflare.com\u002Fen-gb\u002Ftrust-hub\u002Fprivacy-and-data-protection\u002F\" target=\"_blank\">https:\u002F\u002Fwww.cloudflare.com\u002Fen-gb\u002Ftrust-hub\u002Fprivacy-and-data-protection\u002F\u003C\u002Fa>\n\nIf you use the Contact Form on this website, then a service called smtp2go will be used to pass your email on to the trial team. This will involve your email contents being logged with smtp2go for 5 days on a server within the EU, providing a temporary record in the event that we need to troubleshoot any issues.\n\n**Please note**: this Privacy policy does not cover handling of email content by the intended recipient(s).\n\n[Cookie Policy](\u002Fcookie-policy)\n\n## 6. How do we use your personal data?\n\nUnder the GDPR, we must always have a lawful basis for using personal data. This may be because the data is necessary for our performance of a contract with you, because you have consented to our use of your personal data, or because it is in our legitimate business interests to use it. Your personal data may be used for one of the following purposes:\n\n* IP addresses are required by Cloudflare to troubleshoot a number of issues, such as connectivity issues, tracking down specific HTTP responses, tracking DDoS attacks.\n\n## 7. How long will we keep your personal data?\n\nCloudflare processes metadata, including IP addresses, for a limited period of time. Where the technical logs described in Part 10 are kept, they are held for no more than 7 days and are then deleted automatically.\n\n## 8. How and where do we store or transfer your personal data?\n\nWe may store or transfer some or all of your personal data in countries that are not part of the European Economic Area (the “EEA” consists of all EU member states, plus Norway, Iceland, and Liechtenstein). These are known as “third countries” and may not have data protection laws that are as strong as those in the UK and\u002For the EEA. Morph's relationship with Cloudflare with regard to personal data is covered by Cloudflare's standard Data Processing Addendum \n\u003Ca href=\"https:\u002F\u002Fwww.cloudflare.com\u002Fen-gb\u002Fcloudflare-customer-dpa\u002F\" target=\"_blank\">https:\u002F\u002Fwww.cloudflare.com\u002Fen-gb\u002Fcloudflare-customer-dpa\u002F\u003C\u002Fa> which ensures that your personal data is treated just as safely and securely as it would be within the UK and under the GDPR.\n\n## 9. Do we share your personal data?\n\nNo.\n\n## 10. How can I access my personal data?\n\nOur hosting provider may keep short-lived technical logs of requests made to this website, and these can include IP addresses. Where such logs are kept they are held for no more than 7 days and are then deleted automatically. Morph staff can view them in order to diagnose faults with the site, but we do not use them to identify individual visitors and we do not link them to any other information we hold.\n\n## 11. How do I contact you?\n\nTo contact us about anything to do with your personal data and data protection, including to make a subject access request, please use the following details (for the attention of Matthew Brook):\n\nEmail address: info@morph.co.uk\n\nTelephone number: 01524 88 42 88\n\nPostal Address: 8 New Shambles, Kendal, LA9 4TS\n\n## 12. Changes to this Privacy Policy\n\nWe may change this Privacy Policy from time to time. This may be necessary, for example, if the law changes, or if we change our business in a way that affects personal data protection. Any changes will be made available on this website.",{"sectionLabel":353},"Content","\u002Fpages\u002Fprivacy.en",{"title":340},"pages\u002Fprivacy.en","cVige3DPbqEi0V29mMfVuKUNgnxI4vswRyT4b36L7g8",{"id":359,"title":23,"body":38,"description":38,"extension":5,"meta":360,"navigation":15,"path":402,"seo":403,"stem":404,"__hash__":405},"contentPages\u002Fpages\u002Ftaking-part.en.json",{"pageTitle":23,"pageMetadata":361,"page_content":362},{"htmlTitle":23,"htmlDesc":23},[363,369,377,381,397],{"type":52,"title":364,"text":365,"image":366,"sectionSettings":368},"# Taking part","This page explains the ModiFY Study for people who might be interested in joining.",{"url":367,"width":58,"height":59},"modify-header-image-4@2x.png",{"textAlign":90,"theme":105,"sectionLabel":310},{"type":62,"settings":370,"title":371,"text":372,"image":373,"sectionSettings":375},{"imgWidth":64,"imgPosition":65},"## Overview","The ModiFY Study is a clinical trial and oncologists across the UK are recruiting patients with Head and Neck, Renal Cell, and Triple Negative Breast Cancer. \n\nThe study will research a new immunotherapy called Modi-1, to see if it can be used safely in these advanced cancers. Modi-1 is a vaccine that contains three peptides. Peptides are small parts of a protein designed to help your immune system fight cancer.\n\nModi-1 will be administered alone or in combination with checkpoint inhibitors (CPIs).",{"url":374,"width":68,"height":69},"modify-content-image-19.png",{"textAlign":90,"sectionLabel":376},"Overview",{"type":271,"text":378,"video":379,"sectionSettings":380},"The ModiFY Study investigates the Modi-1 vaccine and is designed to explore its safety, whether it triggers your body’s immune system to fight your cancer (immunological activity) and how effective the vaccine is (preliminary efficacy) when given to patients with advanced solid tumours, specifically those with Head and Neck, Renal Cell and Triple Negative Breast cancer. \n\nThe short video provides more information about the ModiFY study",{"vimeoId":274,"videoTitle":275,"videoTranscript":276,"offlineVideo":57},{"sectionLabel":275},{"type":62,"settings":382,"title":383,"text":384,"image":385,"iconList":387,"sectionSettings":394},{"imgWidth":64,"imgPosition":65},"## Modi-1 Patient Information Tools","The Modi-1 Patient Information Tools provide more information about what will happen if you decide to take part in the study. There are 3 different sets of information so it is important that you choose the one that matches your treatment - if in doubt please make sure you check with your healthcare practitioner.",{"url":386,"width":300,"height":301},"modify-content-image-11.png",[388,391],{"icon":389,"content":390},{"iconSize":74,"iconName":138},"Patients with advanced and unresectable (HPV Negative) Head and Neck cancer, Renal Cell cancer and Triple negative breast cancer to receive:\n\n\u003Ca href=\"https:\u002F\u002Fmodi-1-mono.digitrial.com\u002F\" class=\"btn btn-orange-filled\">Modi-1 Only\u003C\u002Fa>\n\n\u003Ca href=\"https:\u002F\u002Fmodi-1-cpi.digitrial.com\u002F\" class=\"btn btn-orange-filled\">Modi-1 + standard of care CPI\u003C\u002Fa>",{"icon":392,"content":393},{"iconSize":74,"iconName":83},"Patients with Head and Neck cancer who are scheduled to have their cancer surgically removed, randomised to receive either:\n\n\u003Ca href=\"https:\u002F\u002Fmodi-1-neoadj.digitrial.com\u002F\" class=\"btn btn-orange-filled\">Modi-1 or Modi-1 + CPI prior to surgery\u003C\u002Fa>",{"textAlign":90,"sectionLabel":395,"customClass":396,"theme":92},"Modi-1 PITs","modi-pits-icons",{"type":62,"settings":398,"text":297,"title":298,"image":399,"sectionSettings":401},{"imgWidth":64,"imgPosition":65},{"url":400,"width":300,"height":301},"modify-content-image-3.png",{"textAlign":90,"sectionLabel":303},"\u002Fpages\u002Ftaking-part.en",{"title":23},"pages\u002Ftaking-part.en","JpxbqXSxWya-bF1r7WnvVWeUo7f1aOMIjHyCEM9pI1s",[407,429,448,468,486,505,524,542,562,581,602,622],{"id":408,"title":409,"body":38,"description":38,"extension":5,"map":98,"meta":410,"navigation":15,"path":425,"publishPage":15,"seo":426,"stem":427,"__hash__":428},"locations\u002Flocations\u002Fedinburgh-cancer-centre.en.json","Edinburgh Cancer Centre",{"locationName":409,"coords":411,"accordionContent":409,"sitePageContent":57,"cards":414},{"lat":412,"lng":413},"55.96166188957894","-3.232709920853224",[415,421],{"type":110,"icon":416,"title":418,"summary":419,"link":420},{"iconSize":113,"iconName":417},"content-map-marker","Address","Western General Hospital\nCrewe Road\nEdinburgh\nEH4 3XU",{"title":57},{"type":110,"icon":422,"title":423,"summary":424},{"iconSize":113,"iconName":138},"Principal Investigator","Dr Stefan Symeonides","\u002Flocations\u002Fedinburgh-cancer-centre.en",{"title":409},"locations\u002Fedinburgh-cancer-centre.en","vKMe-VfxLCu0VvL5pdMDRpJ8efxOI5sHhDtBk97JCEE",{"id":430,"title":431,"body":38,"description":38,"extension":5,"map":98,"meta":432,"navigation":15,"path":444,"publishPage":15,"seo":445,"stem":446,"__hash__":447},"locations\u002Flocations\u002Fimperial-college-healthcare-nhs-trust-london.en.json","Imperial College NHS Trust",{"locationName":431,"coords":433,"accordionContent":431,"sitePageContent":57,"cards":436},{"lat":434,"lng":435},"51.52188681427093","-0.17441711973523813",[437,441],{"type":110,"icon":438,"title":418,"summary":439,"link":440},{"iconSize":113,"iconName":417},"Imperial College London\nHammersmith Hospital\n72 Du Cane Rd\nLondon\nW12 0HS",{"title":57},{"type":110,"icon":442,"title":423,"summary":443},{"iconSize":113,"iconName":138},"Dr David Pinato","\u002Flocations\u002Fimperial-college-healthcare-nhs-trust-london.en",{"title":431},"locations\u002Fimperial-college-healthcare-nhs-trust-london.en","ZIVmBr20B5Xu96l43RVpkgmgIigN4Xeb6m4PkSTLZR8",{"id":449,"title":450,"body":38,"description":38,"extension":5,"map":98,"meta":451,"navigation":15,"path":464,"publishPage":15,"seo":465,"stem":466,"__hash__":467},"locations\u002Flocations\u002Flancashire-teaching-hospitals-nhs-foundation-trust-preston.en.json","Lancashire Teaching Hospitals",{"locationName":450,"coords":452,"accordionContent":455,"sitePageContent":57,"cards":456},{"lat":453,"lng":454},"53.790319943718615","-2.706154857444348","Lancashire Teaching Hospitals NHS Foundation Trust",[457,461],{"type":110,"icon":458,"title":418,"summary":459,"link":460},{"iconSize":113,"iconName":417},"Royal Preston Hospital\nSharoe Green Ln\nFulwood\nPreston\nPR2 9HT",{"title":57},{"type":110,"icon":462,"title":423,"summary":463},{"iconSize":113,"iconName":138},"Dr Dennis Hadjiyiannakis","\u002Flocations\u002Flancashire-teaching-hospitals-nhs-foundation-trust-preston.en",{"title":450},"locations\u002Flancashire-teaching-hospitals-nhs-foundation-trust-preston.en","wYh6lkdVwNS6RgRq010iqHYoI23fVuSeVY5hLDumWqI",{"id":469,"title":470,"body":38,"description":38,"extension":5,"map":98,"meta":471,"navigation":15,"path":482,"publishPage":15,"seo":483,"stem":484,"__hash__":485},"locations\u002Flocations\u002Fmount-vernon.en.json","Mount Vernon Cancer Care",{"locationName":470,"coords":472,"accordionContent":470,"sitePageContent":57,"cards":475},{"lat":473,"lng":474},"51.61552397577085","-0.44557159450681855",[476,479],{"type":110,"icon":477,"title":418,"summary":478},{"iconSize":74,"iconName":417},"Mount Vernon Hospital\nRickmansworth Rd,\nNorthwood \nHA6 2RN",{"type":110,"icon":480,"title":423,"summary":481},{"iconSize":74,"iconName":138},"Dr Saira Khalique","\u002Flocations\u002Fmount-vernon.en",{"title":470},"locations\u002Fmount-vernon.en","zPQ_FS_W5UjoR8CE-JwoHAH4nFnb5QOyfG8v5zVe8HM",{"id":487,"title":488,"body":38,"description":38,"extension":5,"map":98,"meta":489,"navigation":15,"path":501,"publishPage":15,"seo":502,"stem":503,"__hash__":504},"locations\u002Flocations\u002Fnottingham-university-hospitals-cancer-centre.en.json","Nottingham University Hospitals NHS Trust",{"locationName":488,"coords":490,"accordionContent":488,"sitePageContent":57,"cards":493},{"lat":491,"lng":492},"52.99136681939466","-1.1568220192481673",[494,498],{"type":110,"icon":495,"title":418,"summary":496,"link":497},{"iconSize":113,"iconName":417},"Nottingham University Hospitals NHS Trust\nCity Campus\nHucknall Road\nNottingham\nNG 1PB",{"title":57},{"type":110,"icon":499,"title":423,"summary":500},{"iconSize":113,"iconName":138},"Prof Poulam Patel","\u002Flocations\u002Fnottingham-university-hospitals-cancer-centre.en",{"title":488},"locations\u002Fnottingham-university-hospitals-cancer-centre.en","ohyLafKaesr0slZr3wZrcM8g1Sd_u8YrNV_u7n3WucU",{"id":506,"title":507,"body":38,"description":38,"extension":5,"map":98,"meta":508,"navigation":15,"path":520,"publishPage":15,"seo":521,"stem":522,"__hash__":523},"locations\u002Flocations\u002Froyal-surrey-hospital.en.json","Royal Surrey County Hospital",{"locationName":507,"coords":509,"accordionContent":512,"sitePageContent":57,"cards":513},{"lat":510,"lng":511},"51.24123845595901","-0.6084641590267243","Royal Surrey NHS Foundation Trust",[514,517],{"type":110,"icon":515,"title":418,"summary":516},{"iconSize":74,"iconName":417},"Royal Surrey Hospital\nEgerton Rd,\nGuildford\nGU2 7XX",{"type":110,"icon":518,"title":423,"summary":519},{"iconSize":74,"iconName":138},"Dr Agnieszka Michael","\u002Flocations\u002Froyal-surrey-hospital.en",{"title":507},"locations\u002Froyal-surrey-hospital.en","fScM-Mh8IX7VUF4l5yjtZDehwYvlEFj_qZiBC9C9w7o",{"id":525,"title":526,"body":38,"description":38,"extension":5,"map":98,"meta":527,"navigation":15,"path":538,"publishPage":15,"seo":539,"stem":540,"__hash__":541},"locations\u002Flocations\u002Froyal-sussex-county-hospital.en.json","Royal Sussex County Hospital",{"locationName":526,"coords":528,"accordionContent":526,"sitePageContent":57,"cards":531},{"lat":529,"lng":530},"50.821301975203355","-0.11665254201103883",[532,535],{"type":110,"icon":533,"title":418,"summary":534},{"iconSize":113,"iconName":417},"Royal Sussex County Hospital\\\nEastern Road\\\nBrighton\\\nEast Sussex\\\nBN2 5BE",{"type":110,"icon":536,"title":423,"summary":537},{"iconSize":113,"iconName":138},"Dr Rebecca Herbertson","\u002Flocations\u002Froyal-sussex-county-hospital.en",{"title":526},"locations\u002Froyal-sussex-county-hospital.en","CGmb4Y4t3RkrxyS8pOTGbyOdZzLQ28KdTbXrKNjtVko",{"id":543,"title":544,"body":38,"description":38,"extension":5,"map":98,"meta":545,"navigation":15,"path":558,"publishPage":15,"seo":559,"stem":560,"__hash__":561},"locations\u002Flocations\u002Fsheffield-teaching-hospital-nhs-foundation-trust.en.json","Sheffield Teaching Hospital",{"locationName":544,"coords":546,"accordionContent":549,"sitePageContent":57,"cards":550},{"lat":547,"lng":548},"53.379273378736904","-1.4922820439675428","Sheffield Teaching Hospitals NHS Foundation Trust",[551,555],{"type":110,"icon":552,"title":418,"summary":553,"link":554},{"iconSize":113,"iconName":417},"Cancer Clinical Trials Centre\nWeston Park Cancer Centre\nWhitham Road\nSheffield\nS10 2SJ",{"title":57},{"type":110,"icon":556,"title":423,"summary":557},{"iconSize":113,"iconName":138},"Prof Sarah Danson","\u002Flocations\u002Fsheffield-teaching-hospital-nhs-foundation-trust.en",{"title":544},"locations\u002Fsheffield-teaching-hospital-nhs-foundation-trust.en","7j-Q5F_LXEXOIL8nKJnRgW3yGxTVT-3uleTjGfktyDo",{"id":563,"title":564,"body":38,"description":38,"extension":5,"map":38,"meta":565,"navigation":15,"path":577,"publishPage":15,"seo":578,"stem":579,"__hash__":580},"locations\u002Flocations\u002Fchristie-nhs-foundation-trust-manchester.en.json","The Christie Hospital",{"locationName":564,"coords":566,"accordionContent":569,"sitePageContent":57,"cards":570},{"lat":567,"lng":568},"53.42967994220313","-2.2276929328583694","The Christie NHS Foundation Trust",[571,574],{"type":110,"icon":572,"title":418,"summary":573},{"iconSize":113,"iconName":417},"The Christie NHS Foundation Trust\\\n550 Wilmslow Road\\\nManchester\\\nM20 4BX",{"type":110,"icon":575,"title":423,"summary":576},{"iconSize":113,"iconName":138},"Dr Anne Armstrong","\u002Flocations\u002Fchristie-nhs-foundation-trust-manchester.en",{"title":564},"locations\u002Fchristie-nhs-foundation-trust-manchester.en","HUPGKlIgqsM234QorQkd_rLcs3SsrC1jx88cZmDQjYk",{"id":582,"title":583,"body":38,"description":38,"extension":5,"map":98,"meta":584,"navigation":15,"path":598,"publishPage":15,"seo":599,"stem":600,"__hash__":601},"locations\u002Flocations\u002Fthe-clatterbridge-cancer-centre-nhs-foundation-trust-liverpool.en.json","The Clatterbridge Cancer Centre",{"locationName":583,"coords":585,"accordionContent":588,"sitePageContent":57,"cards":589},{"lat":586,"lng":587},"53.33205346956276","-3.0283881304769786","Clatterbridge Cancer Centre NHS Foundation Trust",[590,594],{"type":110,"icon":591,"title":418,"summary":592,"link":593},{"iconSize":113,"iconName":417},"The Clatterbridge Cancer Centre\nNHS Foundation Trust\nClatterbridge Road\nBebington\nWirral\nCH63 4JY",{"title":57},{"type":110,"icon":595,"title":596,"summary":597},{"iconSize":113,"iconName":138},"Chief Investigator","Prof Christian Ottensmeier","\u002Flocations\u002Fthe-clatterbridge-cancer-centre-nhs-foundation-trust-liverpool.en",{"title":583},"locations\u002Fthe-clatterbridge-cancer-centre-nhs-foundation-trust-liverpool.en","YAUAUWLwae5bgexWMm3Mfi5i29JupY7RhHT-8aCObU8",{"id":603,"title":604,"body":38,"description":38,"extension":5,"map":98,"meta":605,"navigation":15,"path":618,"publishPage":15,"seo":619,"stem":620,"__hash__":621},"locations\u002Flocations\u002Ftorbay.en.json","Torbay Hospital",{"locationName":604,"coords":606,"accordionContent":609,"sitePageContent":57,"cards":610},{"lat":607,"lng":608},"50.481545252843986","-3.5530558852643224","Torbay and South Devon NHS Foundation Trust",[611,615],{"type":110,"icon":612,"title":418,"summary":613,"link":614},{"iconSize":74,"iconName":417},"Torbay Hospital\nNewton Rd,\nTorquay\nTQ2 7AA",{"title":57},{"type":110,"icon":616,"title":423,"summary":617},{"iconSize":74,"iconName":138},"Dr Anna Lydon","\u002Flocations\u002Ftorbay.en",{"title":604},"locations\u002Ftorbay.en","aIycRmVIYVYXihOLs2S49423ZQEcuT6eUELNK0Pm8Gg",{"id":623,"title":624,"body":38,"description":38,"extension":5,"map":98,"meta":625,"navigation":15,"path":638,"publishPage":15,"seo":639,"stem":640,"__hash__":641},"locations\u002Flocations\u002Funiversity-college-london-hospital-nhs-foundation-trust.en.json","University College London Hospital",{"locationName":624,"coords":626,"accordionContent":629,"sitePageContent":57,"cards":630},{"lat":627,"lng":628},"51.52580935938624","-0.13747268264514143","University College London Hospitals NHS Foundation Trust",[631,635],{"type":110,"icon":632,"title":418,"summary":633,"link":634},{"iconSize":113,"iconName":417},"University College London Hospital\n235 Euston Road\nLondon\nNW1 2BU",{"title":57},{"type":110,"icon":636,"title":423,"summary":637},{"iconSize":113,"iconName":138},"Dr Rowan Miller","\u002Flocations\u002Funiversity-college-london-hospital-nhs-foundation-trust.en",{"title":624},"locations\u002Funiversity-college-london-hospital-nhs-foundation-trust.en","mwOeFblgFL_M6D6iA3kN0M9y9M_gVg8wfSXZdFeL0Nc",1791287877077]